NKHC1 Activators
NKHC1 Activators are a class of compounds that enhance the function of the NKHC1 protein by manipulating cellular signaling pathways, specifically those involving protein kinase C (PKC) and adenylate cyclase/cAMP. Activators of an ion transporter protein like NKHC1 would be chemicals that increase the protein's ability to move ions across cellular membranes. Direct activators might bind to the protein and induce a conformational change that increases its affinity for ions or enhances the translocation process. This could involve stabilizing the active form of the protein or priming it in a state that is more effective for ion transport.
Some activators might mimic the natural ligands or substrates of NKHC1, binding to the same sites and triggering the transport activity. In the case of allosteric activators, the binding occurs at a different site from where the ions bind, yet it still results in increased transport activity, either by making the protein more responsive to its substrates or by facilitating the transition of the protein to an active state.
Indirect activators would influence the protein's activity without binding to it directly. They could act by upregulating the expression of the NKHC1 gene, leading to the production of more transporter proteins and thus, increased transport capacity. Alternatively, they might interact with cellular signaling pathways that post-translationally modify NKHC1, such as phosphorylation, which is a common regulatory mechanism for activating ion transporters. By enhancing the action of kinases or inhibiting phosphatases that target NKHC1, these activators could increase the intrinsic activity of the protein.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA is a potent activator of protein kinase C (PKC), a kinase known to phosphorylate various kinesin proteins. This phosphorylation could enhance NKHC1's motor function and its ability to transport cargoes along microtubules. | ||||||
1,2-Dioctanoyl-sn-glycerol | 60514-48-9 | sc-202397 sc-202397A | 10 mg 50 mg | $47.00 $254.00 | 2 | |
DAG is a second messenger that activates PKC. Upon activation, PKC can phosphorylate NKHC1, leading to enhanced motor function and cargo transport along microtubules. | ||||||
1-Oleoyl-2-acetyl-sn-glycerol (OAG) | 86390-77-4 | sc-200417 sc-200417A | 10 mg 50 mg | $119.00 $453.00 | 1 | |
OAG is an analog of DAG and thus can activate PKC. The activated PKC potentially phosphorylates NKHC1, thereby enhancing its motor function and cargo transport. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, leading to an increase in cAMP. The increased cAMP can activate PKA, which is known to phosphorylate various kinesin proteins, thereby potentially enhancing the function of NKHC1. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine can activate PKC at nanomolar concentrations. The activated PKC potentially phosphorylates NKHC1, leading to enhanced motor function and cargo transport. | ||||||
Bryostatin 1 | 83314-01-6 | sc-201407 | 10 µg | $245.00 | 9 | |
Bryostatin 1 is a potent activator of PKC. Activated PKC can phosphorylate NKHC1, leading to enhanced motor function and cargo transport. | ||||||
Zoledronic acid, anhydrous | 118072-93-8 | sc-364663 sc-364663A | 25 mg 100 mg | $92.00 $256.00 | 5 | |
Zoledronic acid can inhibit farnesyl diphosphate synthase, leading to decreased prenylation of small GTPases such as Rab, Rho, and Rac. This can indirectly enhance NKHC1 activity by reducing competition for microtubule binding. | ||||||
Manumycin A | 52665-74-4 | sc-200857 sc-200857A | 1 mg 5 mg | $219.00 $634.00 | 5 | |
Manumycin A inhibits farnesyltransferase, reducing prenylation of small GTPases. This can indirectly enhance NKHC1 activity by reducing competition for microtubule binding. | ||||||
GGTI 298 | 1217457-86-7 | sc-361184 sc-361184A | 1 mg 5 mg | $193.00 $838.00 | 2 | |
GGTI-298 is a geranylgeranyltransferase inhibitor. It prevents prenylation of small GTPases, potentially reducing competition for NKHC1's microtubule binding. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. By inhibiting PI3K, it reduces Akt signaling, which can indirectly enhance NKHC1 activity by reducing inhibitory phosphorylations. | ||||||